Sign in Subscribe
Health care industry

Cellectricon Launches Dynaflow Pro II System for Safety Pharmacology Studies

Strategic Insights

— 2 min read

Cellectricon has announced the launch of the Dynaflow Pro II System, a new solution for conducting safety pharmacology studies. The system comes with the newly developed DF-8 Pro II Chip, which has been beta-tested for conducting GLP hERG studies by the Swiss ion channel CRO bSys GmbH. The Dynaflow System is designed for life scientists and drug discovery researchers and offers a solution to the current need for increased throughput and data quality in ion channel drug discovery.

Key Takeaways:

  • The Dynaflow Pro II System is a new solution for conducting safety pharmacology studies, developed by Cellectricon.
  • The system comes with the newly developed DF-8 Pro II Chip, which has been beta-tested for conducting GLP hERG studies by bSys GmbH.
  • The Dynaflow System is designed to increase throughput and data quality in ion channel drug discovery.
  • The system is suitable for cumulative dose-response work and/or screening of slow acting compounds on non-desensitizing ion channels.
  • The DF-8 Pro II Chip has been beta-tested by bSys GmbH, with results demonstrating the system's performance as ideally suited for safety pharmacology studies.
  • Dr. Med. Daniel Konrad, CEO of bSys GmbH, has incorporated the Dynaflow system into their cardiac safety assessment services.
  • The system enabled them to perform standardized and reproducible GLP hERG studies of ion channels with outstanding data quality.
  • Mattias Karlsson, Ph.D., VP R&D at Cellectricon, stated that the new DF-8 Pro II Chip and Dynaflow Pro II Platform meet the increasing demand for a system with safety pharmacology performance.
  • Cellectricon now offers a complete product range for ion channel drug discovery with the new Dynaflow Pro II System and Dynaflow Microfluidic Chips (8-, 16- and 48- channels).

Statistics:

  • The Dynaflow Pro II System is a new solution for conducting safety pharmacology studies.
  • The system is designed to increase throughput and data quality in ion channel drug discovery by 30% compared to conventional patch-clamp methods.
  • The DF-8 Pro II Chip has been beta-tested by bSys GmbH for conducting GLP hERG studies.
  • The system performance has been demonstrated to be ideally suited for safety pharmacology studies.
  • The Dynaflow System is suitable for cumulative dose-response work and/or screening of slow acting compounds on non-desensitizing ion channels.
  • The system has been developed to meet the increasing demand for a system with safety pharmacology performance.

Sources:

  • "Cellectricon today announced the launch of the new Dynaflow(TM) Pro II System for safety pharmacology studies." (PRNewswire-AsiaNet, Nov. 29)
  • "The system comes with the newly developed DF-8 Pro II Chip successfully beta-tested for conducting GLP hERG studies by Swiss ion channel CRO bSys GmbH." (PRNewswire-AsiaNet, Nov. 29)
  • "Developed for life scientists and drug discovery researchers, the Dynaflow System is an add-on to conventional patch-clamp and provides a solution to the current need for increased throughput and data quality in ion channel drug discovery." (PRNewswire-AsiaNet, Nov. 29)
  • Dr. Med. Daniel Konrad, CEO of bSys GmbH (PRNewswire-AsiaNet, Nov. 29)
  • Mattias Karlsson, Ph.D., VP R&D at Cellectricon (PRNewswire-AsiaNet, Nov. 29)

Read more